Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
Remdesivir was among the first antiviral therapies to be tested in RCTs for COVID-19. At a follow-up of 28-29 days, the use of remdesivir was not associated with a significant decrease in time to clinical improvement. Moderate and very low certainty of evidence showed there was no significant difference in deaths and developing any adverse events. Remdesivir was associated with higher rates of hospital discharge, but not with a significant reduction in the meantime to clinical improvement or mor
